Core Insights - Pfizer announced a positive study outcome for a weight-loss drug candidate, indicating potential growth in this therapeutic area [1] - The company also projected a decline in profits, attributing this to the pricing and tariff policies implemented during the Trump administration [1] Group 1: Drug Development - Pfizer's weight-loss drug candidate has shown promising results in a recent study, which could enhance its portfolio in the obesity treatment market [1] Group 2: Financial Outlook - The company forecasts a profit decline, highlighting the adverse effects of the Trump administration's policies on drug pricing and tariffs [1]

Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer’s recent game plan. Cramer had mixed feelings about the stock, as he stated: On the other hand, I worry about Pfizer because while its stock has a terrific yield, I haven’t seen anything of late that would make me feel there’s a new blockbuster here that could move the needle. Although I was thinking about when I saw Verizon do that today, which was also a bond that turned into a stock… it maybe could happen to Pfizer. Photo by Spencer Davis on ...

Core Viewpoint - Pfizer reported a decline in fourth-quarter sales due to decreasing demand for its Covid-19 vaccine and antiviral drug [1] Group 1: Company Performance - Pfizer's fourth-quarter sales were lower compared to previous periods, indicating a significant drop in revenue from Covid-19 related products [1]

Core Insights - Pfizer's experimental obesity drug, acquired through Metsera, demonstrated significant weight loss in a mid-stage trial, with patients losing up to 12.3% of their weight compared to placebo at week 28 [1] - The injection's weight loss efficacy was noted to be 10.5% when considering all patients, regardless of discontinuations [1] Group 1 - The data suggests that the injection can be administered less frequently than existing treatments without losing efficacy, positioning Pfizer favorably in a market currently led by Eli Lilly and Novo Nordisk [2] - Pfizer plans to initiate 10 phase three trials for the injection, named PF'3944, within the year [2] Group 2 - Dr. Jim List, Pfizer's chief internal medicine officer, stated that the topline results support the potential of PF'3944 as a monthly treatment with competitive efficacy [3] - The trial involved patients transitioning from weekly to monthly injections, with no plateau in weight loss observed after the switch [3]

格隆汇2月3日｜辉瑞制药第四季度营收175.6亿美元，预估169.4亿美元；第四季度调整后每股收益0.66 美元。辉瑞制药仍预测2026年营收595亿美元至625亿美元；预测2026年调整后每股收益2.80美元至3.00 美元。2026年指引反映了最惠国药品定价和特朗普处方药政策预计带来的不利影响。 来源：格隆汇APP ...

Pfizer also releases positive top-line results from a trial for its injectable GLP-1 receptor agonist in adults with obesity. ...

Financial Performance - Full-Year 2025 revenues totaled $62.6 billion, reflecting a 2% year-over-year operational decline; excluding contributions from Paxlovid and Comirnaty, revenues grew 6% operationally[4] - Full-Year 2025 reported diluted EPS was $1.36, while adjusted diluted EPS was $3.22, representing a 3% decline year-over-year[4] - Fourth-Quarter 2025 revenues were $17.6 billion, a 3% year-over-year operational decline; excluding contributions from Paxlovid and Comirnaty, revenues grew 9% operationally[4] - Full-year 2025 total revenues were $62,579 million, down 2% from $63,627 million in 2024[35] - Fourth-quarter 2025 revenues totaled $15.141 billion, a decrease of 8% compared to the prior year, primarily due to a decline in COVID-19 product revenues[20] - Full-year 2025 net income attributable to Pfizer Inc. common shareholders was $7.771 billion, with an adjusted diluted EPS of $3.22, compared to $1.36 in 2024[46] - Net income attributable to Pfizer Inc. common shareholders for Q4 2025 was a loss of $1,648 million, compared to a profit of $410 million in Q4 2024[35] Revenue Guidance and Expectations - Pfizer reaffirms its full-year 2026 financial guidance, expecting revenues in the range of $59.5 to $62.5 billion and adjusted diluted EPS between $2.80 and $3.00[10] - The 2026 revenue guidance includes approximately $5 billion from COVID-19 products and anticipates a negative revenue impact of about $1.5 billion due to certain products losing exclusivity[10] - The anticipated unfavorable revenue impact due to generic and biosimilar competition is approximately $1.5 billion[30] Research and Development - Pfizer advanced 11 key pivotal study starts in 2025 and plans approximately 20 key pivotal study starts for 2026, focusing on key therapeutic areas[3] - In 2025, Pfizer invested $10.4 billion in internal research and development and approximately $8.8 billion in business development transactions, including the Metsera acquisition[11] - Fourth-quarter 2025 R&D expenses increased by 4% to $3.116 billion, driven by spending in oncology and obesity product candidates[19] - Research and development expenses for Q4 2025 were $3,206 million, an increase of 6% from $3,035 million in Q4 2024[35] Product Performance - Comirnaty and Paxlovid revenues declined significantly, down 35% and 70% operationally, respectively, due to lower COVID-19 infections and vaccination rates[16] - The operational decrease in full-year 2025 revenues was primarily driven by lower demand for Paxlovid and Comirnaty, partially offset by growth from products like Vyndaqel and Eliquis[21] - Fourth-quarter operational revenue reflected higher revenues for Abrysvo, up 136%, and oncology biosimilars, up 76%[14] - Eliquis revenue increased by 10% to $2,020 million in 2025, up from $1,832 million in 2024[53] - Specialty Care revenues rose by 8% to $4,771 million in 2025, compared to $4,438 million in 2024[53] - Oncology revenues increased by 9% to $4,435 million in 2025, up from $4,064 million in 2024[53] - Paxlovid sales significantly dropped to $2.362 billion, a 59% decrease from $5.716 billion in 2024[58] Shareholder Returns - The company returned $9.8 billion to shareholders through cash dividends, equating to $1.72 per share of common stock[11] Acquisitions and Collaborations - Pfizer completed the acquisition of Metsera for approximately $7.0 billion, enhancing its portfolio in obesity and cardiometabolic diseases[26] - Pfizer announced a global collaboration with YaoPharma for the development of YP05002, with an upfront payment of $150 million and potential milestone payments up to $1.935 billion[26] Tax and Financial Adjustments - The effective tax rate on adjusted income for the fourth quarter of 2025 was 23.3%, up from 18.9% in the prior year[19] - Pfizer's effective tax rate for full-year 2025 was 0.1%, a notable decrease from 4,220.5% in 2024, attributed to favorable changes in jurisdictional earnings mix and tax benefits[41] - The company recognized $4.363 billion in asset impairments in Q4 2025, significantly higher than the $2.946 billion in Q4 2024, primarily related to changes in development plans[41] Market Challenges and Risks - Competition from new product entrants, generic products, and biosimilars poses a significant challenge to the company's market position[62] - The company faces uncertainties regarding the demand for COVID-19 products, which may lead to reduced revenues and excess inventory[62] - Regulatory changes, including the Inflation Reduction Act of 2022, could impact drug pricing and reimbursement processes, affecting overall revenue[64] - The company is exposed to risks related to climate change, geopolitical instability, and potential disruptions from natural disasters[64] - Legal proceedings and regulatory evaluations may result in product recalls or withdrawals, impacting financial performance[64] - Fluctuations in interest rates and foreign currency exchange rates could affect financial results and operational costs[62] - Cybersecurity threats and potential disruptions to information technology systems pose risks to operational integrity[65]

每经AI快讯，2月3日，辉瑞股价盘前下跌2.1%。 （文章来源：每日经济新闻） ...

Albert Bourla, CEO of Pfizer, speaking on Squawk on the Street at the World Economic Forum in Davos, Switzerland on Jan. 20, 2026.Pfizer on Tuesday reported fourth-quarter results that topped estimates even amid dwindling demand for its Covid products, while reaffirming its modest 2026 guidance that rattled investors in December.The pharmaceutical giant is looking to longer-term investments in its pipeline, including its $10 billion acquisition of the obesity biotech Metsera, to counter waning Covid product ...

每经AI快讯，2月3日消息，辉瑞制药第四季度营收175.6亿美元；第四季度调整后每股收益0.66美元。 公司仍然预测2026年营收595亿美元至625亿美元。 ...